title: New methods for estimating local electrical activation rate during atrial fibrillation.
abstract: BACKGROUND
  Dominant frequency (DF) analysis is sometimes limited in its characterization of atrial fibrillation (AF), thus better methodology is needed.
  
  
  OBJECTIVE
  To develop methods for analyzing the AF signal without transformation to frequency space, and to compare the methods to DF analysis using both real and simulated data.
  
  
  METHODS
  Electrograms were obtained in 11 patients with paroxysmal or persistent AF. Atrial rate (AR) was estimated retrospectively from 8.4-s intervals acquired at 8 sites, using DF and 2 new methods: (1) Signals were converted into merged deflections (time complexes [TC]). Mean peak-to-peak cycle length was used to estimate AR. (2) The ensemble average (EA) was calculated with window size (w) ranging from 50 to 500 ms (frequency f = 2 to 20 Hz). The dominant peak in the root-mean-square power spectrum of EA versus w was used to estimate AR. Methods were compared using patient data, and in simulations using a Hanning pulse (2-mV peak, 50-ms duration, 120-ms period) with additive random noise, amplitude changes, and phase shift. Data from 10 atrial flutter patients were used to validate rate estimation under static conditions.
  
  
  RESULTS
  From pooled AF data (N = 88 sites), mean atrial rate was 5.71 Hz (EA), 5.96 Hz (TC), and 5.72 Hz (DF). The mean absolute rate difference was 0.65 Hz (EA-TC), 0.58 Hz (EA-DF), and 0.50 Hz (TC-DF). In simulations, DF, TC, and EA, respectively, correctly predicted rate with additive random noise up to 0.13 mV, 1.4 mV, and 15.2 mV, random phase shift up to 46.3 ms, 28.8 ms, and 51.3 ms, and random amplitude variation ranging from 0 to 4 mV, 1.3 to 2.7 mV, and 0 to 4 mV. All methods accurately estimated rate during atrial flutter.
  
  
  CONCLUSIONS
  Accurate rate estimation depends on signal periodicity and is influenced by random noise. The EA provides an accurate rate estimate of the periodic component of AF even at high noise levels.
authors.affiliation: Department of Pharmacology, Columbia University, New York, New York 10032, USA. ejc6@columbia.edu
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Ciaccio
authors.forename: Angelo B
authors.initials: AB
authors.lastname: Biviano
authors.forename: William
authors.initials: W
authors.lastname: Whang
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Wit
authors.forename: Hasan
authors.initials: H
authors.lastname: Garan
authors.forename: James
authors.initials: J
authors.lastname: Coromilas
mesh_terms: D001281:Atrial Fibrillation / Q000175:diagnosis / Q000503:physiopathology* / Q000601:surgery; D018780:Body Surface Potential Mapping / Q000379:methods*; D017115:Catheter Ablation / Q000379:methods; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000503:physiopathology* / Q000601:surgery; D006339:Heart Rate / Q000502:physiology*; D006801:Humans; D011667:Pulmonary Veins / Q000294:innervation / Q000503:physiopathology; D012189:Retrospective Studies